Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours
about
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG.Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicitySequelae and survivorship in patients treated with (131)I-MIBG therapy¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.Radionuclide therapy of adrenal tumors.Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
P2860
Q35675435-68304B46-CF4A-403D-A2D6-C5B006A39141Q35750737-8A543519-09EB-4A59-9C91-7C064A3E289FQ36775316-0317C37B-AEC3-4039-B3F8-314800A20435Q37081870-55E55A5B-E643-4C8C-8CE4-7BD392C62566Q37990403-5C54A9C6-55BD-4B0B-9223-FB06485F270AQ38020428-205FAEE9-0EFF-4983-AE57-22B00619E74FQ38542762-B41BD49B-5F57-4DE7-BCDA-B9653883735C
P2860
Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Assessment of the efficacy and ...... astatic neuroendocrine tumours
@ast
Assessment of the efficacy and ...... astatic neuroendocrine tumours
@en
type
label
Assessment of the efficacy and ...... astatic neuroendocrine tumours
@ast
Assessment of the efficacy and ...... astatic neuroendocrine tumours
@en
prefLabel
Assessment of the efficacy and ...... astatic neuroendocrine tumours
@ast
Assessment of the efficacy and ...... astatic neuroendocrine tumours
@en
P2093
P2860
P356
P1476
Assessment of the efficacy and ...... astatic neuroendocrine tumours
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604273
P407
P577
2008-02-19T00:00:00Z